Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies

Percutaneous ablation is a mainstay of treatment for early stage, unresectable hepatocellular carcinoma (HCC). Recent advances in technology have created multiple ablative modalities for treatment of this common malignancy. The purpose of this review is to familiarize readers with the technical and...

Descripción completa

Detalles Bibliográficos
Autores principales: Huber, Timothy C, Bochnakova, Teodora, Koethe, Yilun, Park, Brian, Farsad, Khashayar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476177/
https://www.ncbi.nlm.nih.gov/pubmed/34589446
http://dx.doi.org/10.2147/JHC.S268300
_version_ 1784575552173113344
author Huber, Timothy C
Bochnakova, Teodora
Koethe, Yilun
Park, Brian
Farsad, Khashayar
author_facet Huber, Timothy C
Bochnakova, Teodora
Koethe, Yilun
Park, Brian
Farsad, Khashayar
author_sort Huber, Timothy C
collection PubMed
description Percutaneous ablation is a mainstay of treatment for early stage, unresectable hepatocellular carcinoma (HCC). Recent advances in technology have created multiple ablative modalities for treatment of this common malignancy. The purpose of this review is to familiarize readers with the technical and clinical aspects of both existing and emerging percutaneous treatment options for HCC.
format Online
Article
Text
id pubmed-8476177
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84761772021-09-28 Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies Huber, Timothy C Bochnakova, Teodora Koethe, Yilun Park, Brian Farsad, Khashayar J Hepatocell Carcinoma Review Percutaneous ablation is a mainstay of treatment for early stage, unresectable hepatocellular carcinoma (HCC). Recent advances in technology have created multiple ablative modalities for treatment of this common malignancy. The purpose of this review is to familiarize readers with the technical and clinical aspects of both existing and emerging percutaneous treatment options for HCC. Dove 2021-09-23 /pmc/articles/PMC8476177/ /pubmed/34589446 http://dx.doi.org/10.2147/JHC.S268300 Text en © 2021 Huber et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Huber, Timothy C
Bochnakova, Teodora
Koethe, Yilun
Park, Brian
Farsad, Khashayar
Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies
title Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies
title_full Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies
title_fullStr Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies
title_full_unstemmed Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies
title_short Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies
title_sort percutaneous therapies for hepatocellular carcinoma: evolution of liver directed therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476177/
https://www.ncbi.nlm.nih.gov/pubmed/34589446
http://dx.doi.org/10.2147/JHC.S268300
work_keys_str_mv AT hubertimothyc percutaneoustherapiesforhepatocellularcarcinomaevolutionofliverdirectedtherapies
AT bochnakovateodora percutaneoustherapiesforhepatocellularcarcinomaevolutionofliverdirectedtherapies
AT koetheyilun percutaneoustherapiesforhepatocellularcarcinomaevolutionofliverdirectedtherapies
AT parkbrian percutaneoustherapiesforhepatocellularcarcinomaevolutionofliverdirectedtherapies
AT farsadkhashayar percutaneoustherapiesforhepatocellularcarcinomaevolutionofliverdirectedtherapies

Ejemplares similares